Moderna announces first participants dosed in study evaluating COVID-19 booster vaccine candidates

Study will enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates (20 or 50 µg of mRNA-1273.351, or mRNA-1273.211 [mRNA-1273+mRNA-1273.351]) against the B.1.351 variant first identified in South Africa.

Biospace Inc.